Obtaining a booster dose of coronavirus disease 2019 (COVID-19) vaccine is required to maintain the protective level of neutralizing antibodies and therefore herd immunity in the community, and the success of booster dose programs depends on public acceptance. The aim of this study was to determine the acceptance of a booster dose of COVID-19 vaccine and its drivers and barriers in Indonesia. A cross-sectional survey was conducted in the provinces of Indonesia between 1 and 15 August 2022. Individuals who completed the primary series of the COVID-19 vaccine were asked about their acceptance of a booster dose. Those who refused the booster dose were questioned about their reasons. A logistic regression was used to determine the determinants associated with rejection of a booster dose of COVID-19 vaccine. A total of 2935 respondents were included in the final analysis. With no information on the efficacy and safety of the COVID-19 vaccine, 95% of respondents agreed to receive a booster dose if it were provided for free by the government. This acceptance was reduced to only 50.3% if the vaccine had a 75% efficacy with a 20% chance of side effects. The adjusted logistic regression analysis indicated that there were eight factors associated with the rejection of the booster dose: age, marital status, religion, occupation, type of the first two vaccines received, knowledge regarding the importance of the booster dose, belief that natural immunity is sufficient to prevent COVID-19 and disbelief in the effectiveness of the booster dose. In conclusion, the hesitancy toward booster doses in Indonesia is influenced by some intrinsic factors such as lack of knowledge on the benefits of the booster dose, worries regarding the unexpected side effects and concerns about the halal status of the provided vaccines and extrinsic determinants such as the effectiveness and safety of the vaccine. These findings suggest the need for more campaigns and promotions regarding the booster dose benefits to increase its acceptance.

Willingness to pay (WTP) for booster doses of coronavirus disease 2019 (COVID-19) vaccines is an under studied research topic. Therefore, the current study aimed to investigate the WTP for the booster doses of COVID-19 vaccines and its predictors in Indonesia using an online survey distributed all over the provinces of this low-middle-income country. The WTP was evaluated using a basic dichotomous contingent valuation approach, and its associated determinants were evaluated using a linear regression model. Out of 2935 responders, 66.2% (1942/2935) were willing to pay for a booster dose of the COVID-19 vaccine. The majority of respondents (63.5%) were willing to pay within a price range of 100,000–500,000 Indonesian rupiah (IDR), i.e., USD 6.71–33.57. Being older than 40 years, having a higher educational level, having a higher income, knowing and understanding that booster doses were important, and having a vaccine status that is certified halal (permissible in Islamic law), were all associated with a higher WTP for the booster dose of COVID-19 vaccines. The study findings imply that the WTP for a booster dose of COVID-19 vaccination in Indonesia is lower compared to acceptance of vaccines provided free of charge. This WTP data can be utilized to develop a pricing scheme for the booster doses of COVID-19 vaccination in the country with potential benefits in other low-income countries. The government may be required to provide subsidies for the herd immunity vaccination process to proceed as anticipated. Furthermore, the public community must be educated on the importance of vaccination as well as the fact that the COVID-19 epidemic is far from being over.

Background: Silica, asbestos and coal dust are associated with pneumoconiosis in mining workers. The International Labor Organization (ILO) reports that 30-50% of workers in developing countries are diagnosed with pneumoconiosis. This study aims to identify pneumoconiosis in limestone mining workers in Indonesia. Method: This cross-sectional study involved 73 subjects of limestone mining workers in Citatah Village, West Bandung Regency, Indonesia. Two conclusions were similar from three AIR-Pneumo certified photo readers by blind reading and using the ILO guidelines. Result: Pneumoconiosis was found in 11/73 (15.1%). The median age of the pneumoconiosis group was older than the non-pneumoconiosis group (51 [33-63] vs. 37.5 [18-85] age in years, p = 0.013). All subjects in the pneukoniosis group worked> 6 years (p = 0.001). The highest dust concentration was in the pneumoconiosis group compared to the non-pneumoconisosis group (61.41 ± 103.98 vs. 14.92 ± 55.17 mg / m3, p = 0.030). This study showed that the length of work and the level of dust in the mine were risk factors for pneumoconiosis, although not significant (OR = 14.6, p = 0.999 and OR = 7,171, p = 0.998). Conclusion: The proportion of pneumoconiosis in lime mining workers in this study was 15.1%. Length of work and dust levels in the mine are risk factors for pneumoconiosis; but not meaningful in this study.

Background: Diabetes mellitus (DM) is a risk factor for tuberculosis (TB) morbidity and mortality. Increasing cases of type 2 DM in the world increases the risk of developing TB. The frequency of DM in TB patients was reported to be around 10-15% and the prevalence of this infectious disease was 2-5 times higher in diabetic patients compared to non-diabetics. Hemoptysis is a respiratory symptom which can be life threatening. Tuberculosis and bronchiectasis are the two most common ethology of hemoptysis, while TB with DM are the cause of recurrent hemoptysis. Methods: This was case control study which used the medical records data of diabetic patients infected with TB who experienced hemoptysis and no hemoptysis, treated at Fatmawati General Hospital during 2017. Sampling method was total sampling. Results: There were 12 hemoptysis patients with DM comorbidity and 31 patients without DM comorbidity. As many as 58% of patients with DM had new cases of pulmonary TB and 42% had history of treatment completion. The correlation between hemoptysis of TB patients with DM compared to without DM obtained a relative risk of 1.535 (95% CI=0.677-2.618) Conclusion: The proportion of hemoptysis in TB patients with DM comorbidity was 10.3%. Diabetes Mellitus was a risk factor for hemoptysis 1.535 times higher compared to TB patients without DM but statistically not significant. (J Respir Indo. 2020; 40(3): 144-9)

Objectives: The Indonesian Ministry of Health launched isoniazid preventive therapy (IPT) in 2016, with general practitioners (GPs) at the frontline of this program. However, the extent to which GPs have internalized this program remains uncertain. The aim of this study was to identify the knowledge and attitudes of GPs towards the IPT program in Indonesia.Methods: This study used an online, self-administered questionnaire distributed via e-mail and social messaging services. A logistic regression model was employed to identify the explanatory variables influencing the level of knowledge and attitudes toward IPT among GPs in Indonesia. An empirical analysis was conducted separately for each response variable (knowledge and attitudes).Results: Of the 418 respondents, 128 (30.6%) had a good knowledge of IPT. Working at a public hospital was the only variable associated with good knowledge, with an adjusted odds ratio (aOR) of 1.69 (95% confidence interval [CI], 1.02 to 2.81). Furthermore, 279 respondents (66.7%) had favorable attitudes toward IPT. In the adjusted logistic regression analysis, good knowledge (aOR, 0.55; 95% CI, 0.34 to 0.89), 1-5 years of work experience (aOR, 2.09; 95% CI, 1.21 to 3.60), and having experienced IPT training (aOR, 0.48; 95% CI, 0.25 to 0.93), were significantly associated with favorable attitudes.Conclusions: In general, GPs in Indonesia had favorable attitudes toward IPT. However, their knowledge of IPT was limited. GPs are an essential element of the IPT program in the country, and therefore, adequate information dissemination to improve their understanding is critical for the long-term viability and quality of the IPT program in Indonesia.